Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    DEN120023
    Manufacturer
    Date Cleared
    2014-01-29

    (426 days)

    Product Code
    Regulation Number
    876.1330
    Type
    Direct
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Device Name :

    GIVEN PILLCAM COLON 2 CAPSULE ENDOSCOPY SYSTEM

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The PillCam COLON 2 Capsule Endoscopy System is indicated to provide visualization of the colon. It is intended to be used for detection of colon polyps in patients after an incomplete optical colonoscopy with adequate preparation, and a complete evaluation of the colon was not technically possible.

    Device Description

    The PillCam® COLON 2 capsule endoscopy system includes a single-use ingestible capsule designed to acquire video images during natural propulsion through the digestive system. It is specifically designed to visualize the complex anatomy of the colon. The PillCam COLON 2 capsule is designed to withstand the mechanical forces and chemical environment of the digestive system. The system is comprised of four main subsystems; (1) the ingestible PillCam COLON 2 capsule, (2) the DR 3 PillCam® Recorder, (3) the RAPID® software, and (4) the Given® Workstation.

    AI/ML Overview

    1. A table of acceptance criteria and the reported device performance

    Acceptance Criteria (Polyp Detection by CCE vs. OC)Performance for Polyps ≥ 6 mmPerformance for Polyps ≥ 10 mm
    Positive Percent Agreement68.8% (95% CI 61.7-75.2%)64.9% (95% CI 53.2-75.5%)
    Negative Percent Agreement81.3% (95% CI 77.6-84.6%)92.9% (95% CI 90.6-94.8%)

    Note: The document does not explicitly state numerical acceptance criteria values, but rather presents the study's performance characteristics as part of the overall demonstration of effectiveness. The table above reflects the reported performance that supports the device's acceptance.

    2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    • Sample Size for Effectiveness Analysis: 700 subjects successfully completed an investigation with both CCE and OC and were included in the effectiveness analysis.
    • Data Provenance: Prospective, multi-center study.
    • Country of Origin: 11 enrollment sites in the US and 6 in Israel.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    The document states that a "central reader" interpreted the CCE results. For the optical colonoscopy (OC) results, "colonoscopists" evaluated their findings. The number and specific qualifications (e.g., years of experience) of these experts are not explicitly stated in the provided text.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    The document mentions an initial phase where "colonoscopists were blinded to CCE results when evaluating their OC findings." Following this, if a polyp detected on CCE was not identified by the initial colonoscopy, "the results of the CCE evaluation were unblinded and the colonoscopy was repeated in a second attempt to identify the polyp identified on CCE." This suggests a form of sequential adjudication or unblinding with repeat examination rather than a consensus-based adjudication (like 2+1 or 3+1). The "reference OC polyp chosen for the final determination was the one that was in favor of the device" when there were multiple equally large polyps, which implies a specific rule for handling discrepancies.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    The study was a "multi-center study" comparing CCE (the device) with optical colonoscopy (OC). It primarily evaluated the standalone performance of the CCE system against OC as the ground truth. There is no information provided about a Multi-Reader Multi-Case (MRMC) comparative effectiveness study involving human readers with and without AI assistance. The focus is on the device's ability to detect polyps, not on enhancing human reader performance using the device as an AI assistant.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    Yes, a standalone performance evaluation was conducted. The study "compared CCE with optical colonoscopy (OC) for agreement on absence or presence of colon polyps." The CCE system, including its RAPID software for video viewing and report generation, functions as an algorithm-driven system that outputs video for interpretation. The performance metrics (positive and negative percent agreement) specifically refer to the CCE as a device, implying standalone performance in detecting polyps. The "centralized reader" interpreted the CCE results, but the CCE itself is the classification device.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

    The ground truth used was Optical Colonoscopy (OC) findings, specifically the identification and sizing of colon polyps (≥6 mm or ≥10 mm). OC is considered a clinically acceptable alternative structural imaging method.

    8. The sample size for the training set

    The provided document does not specify the sample size for a training set. The clinical study described is for evaluating the performance of the already developed device, not for training it.

    9. How the ground truth for the training set was established

    Since no information on a training set is provided, how its ground truth was established is not detailed in this document.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1